AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for GDP-fucose protein O-fucosyltransferase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9Y2G5

UPID:

OFUT2_HUMAN

Alternative names:

Peptide-O-fucosyltransferase 2

Alternative UPACC:

Q9Y2G5; Q6PJV1; Q7Z4N0; Q8WWU6; Q9BQS4; Q9BQS5; Q9UFY3

Background:

GDP-fucose protein O-fucosyltransferase 2, also known as Peptide-O-fucosyltransferase 2, plays a crucial role in protein modification. It catalyzes the attachment of fucose to serine or threonine residues in specific protein sequences, impacting various protein families including ADAMTS and thrombospondin. This enzymatic activity is essential for proper protein secretion and has implications in cellular processes such as epithelial to mesenchymal transition.

Therapeutic significance:

Understanding the role of GDP-fucose protein O-fucosyltransferase 2 could open doors to potential therapeutic strategies. Its involvement in critical protein modification pathways suggests a foundational role in cellular function and disease modulation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.